Angiotensin Receptor Antagonists

"Angiotensin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.

Descriptor ID	D057911
MeSH Number(s)	D27.505.519.162
Concept/Terms	Angiotensin Receptor Antagonists Angiotensin Receptor Antagonists Antagonists, Angiotensin Receptor Receptor Antagonists, Angiotensin Angiotensin Receptor Blockers Receptor Blockers, Angiotensin Angiotensin II Receptor Antagonists Angiotensin II Receptor Antagonists Angiotensin II Receptor Blockers

Below are MeSH descriptors whose meaning is more general than "Angiotensin Receptor Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Angiotensin Receptor Antagonists [D27.505.519.162]

Below are MeSH descriptors whose meaning is more specific than "Angiotensin Receptor Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiotensin Receptor Antagonists" by people in this website by year, and whether "Angiotensin Receptor Antagonists" was a major or minor topic of these publications.

Bar chart showing 130 publications over 24 distinct years, with a maximum of 14 publications in 2018 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	1	1	2
1995	1	0	1
1996	0	1	1
1997	3	0	3
1998	1	2	3
1999	1	1	2
2002	3	5	8
2003	2	1	3
2004	1	0	1
2008	0	1	1
2009	0	1	1
2010	2	2	4
2011	2	1	3
2012	1	0	1
2013	4	0	4
2014	6	1	7
2015	7	2	9
2016	10	3	13
2017	3	4	7
2018	6	8	14
2019	6	8	14
2020	3	7	10
2021	5	6	11
2022	0	7	7

Below are the most recent publications written about "Angiotensin Receptor Antagonists" by people in Profiles.

Wijkman MO, Claggett B, Vaduganathan M, Cunningham JW, Rørth R, Jackson A, Packer M, Zile M, Rouleau J, Swedberg K, Lefkowitz M, Shah SJ, Pfeffer MA, McMurray JJV, Solomon SD. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022 06 18; 21(1):110.

View in: PubMed
Masarone D, Tedford RJ, Melillo E, Petraio A, Pacileo G. Angiotensin-converting enzyme inhibitor therapy after heart transplant: From molecular basis to clinical effects. Clin Transplant. 2022 07; 36(7):e14696.

View in: PubMed
Cikes M, Planinc I, Claggett B, Cunningham J, Milicic D, Sweitzer N, Senni M, Gori M, Linssen G, Shah SJ, Packer M, Pfeffer M, Zile MR, Anand I, Chiang LM, Lam CSP, Redfield M, Desai AS, McMurray JJV, Solomon SD. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2022 05; 10(5):336-346.

View in: PubMed
Curtain JP, Campbell RT, Petrie MC, Jackson AM, Abraham WT, Desai AS, Dickstein K, Køber L, Rouleau JL, Swedberg K, Zile MR, Solomon SD, Jhund PS, McMurray JJV. Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. JACC Heart Fail. 2022 06; 10(6):415-427.

View in: PubMed
Pabón MA, Cunningham JW, Claggett BL, Packer M, Zile M, Pfeffer MA, Lefkowitz M, Shi V, Rizkala A, McMurray JJV, Solomon SD, Vaduganathan M. Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF. Eur J Heart Fail. 2022 04; 24(4):672-677.

View in: PubMed
Curtain JP, Jackson AM, Shen L, Jhund PS, Docherty KF, Petrie MC, Castagno D, Desai AS, Rohde LE, Lefkowitz MP, Rouleau JL, Zile MR, Solomon SD, Swedberg K, Packer M, McMurray JJV. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. Eur J Heart Fail. 2022 03; 24(3):551-561.

View in: PubMed
Mc Causland FR, Lefkowitz MP, Claggett B, Packer M, Senni M, Gori M, Jhund PS, McGrath MM, Rouleau JL, Shi V, Swedberg K, Vaduganathan M, Zannad F, Pfeffer MA, Zile M, McMurray JJV, Solomon SD. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 Sep; 24(9):1591-1598.

View in: PubMed
Daoud A, Ali H, Rao V, Rohan V, Soliman K. ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients. Ren Fail. 2021 12; 43(1):1463-1464.

View in: PubMed
Jackson AM, Jhund PS, Anand IS, Düngen HD, Lam CSP, Lefkowitz MP, Linssen G, Lund LH, Maggioni AP, Pfeffer MA, Rouleau JL, Saraiva JFK, Senni M, Vardeny O, Wijkman MO, Yilmaz MB, Saito Y, Zile MR, Solomon SD, McMurray JJV. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021 09 21; 42(36):3741-3752.

View in: PubMed
Gori M, Senni M, Claggett B, Liu J, Maggioni AP, Zile M, Prescott MF, Van Veldhuisen DJ, Zannad F, Pieske B, Lam CSP, Rouleau J, Jhund P, Packer M, Pfeffer MA, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. JACC Heart Fail. 2021 09; 9(9):627-635.

View in: PubMed

People

Explore

Similar Concepts

Top Journals